RxDoctor Payments Data

Gregory Schuchard, MD

Interventional Cardiology · Bemidji, MNNPI 1881669810

Payments from drug & device makers

What this record shows

Abbott accounts for 75.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $2,568 and has fallen 98.6% since, to $35 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MN, where the typical reported total is $5,396.

$3,258in general payments, 2019–2025

Across 42 payments — averaging $77.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Heartflow, Inc.$138
  • Impulse Dynamics (USA) Inc.$81
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$78
  • Alnylam Pharmaceuticals Inc.$72
  • Biotronik Inc.$70
  • plus $350 from 11 others

What the payments were for

  • Travel & lodging$1,48746%
  • Food & beverage$1,77154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,258 in reported general payments places this provider in the 35th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$86,909
Medicare patients
619
Services billed
1,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$39,475
BrilintaTicagrelor32$19,636
XareltoRivaroxaban17$12,193
ClopidogrelClopidogrel Bisulfate170$2,903
Atorvastatin Calcium100$1,226
Metoprolol Succinate70$842
Rosuvastatin Calcium68$701
Losartan Potassium59$640
Ezetimibe31$612
Spironolactone57$505
Amlodipine Besylate52$493
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$417
Lisinopril25$320
Metoprolol Tartrate29$203
Carvedilol31$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$39,47539 claims
Johnson & JohnsonXarelto$13$12,19317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 84 interventional cardiology providers in Minnesota.

Other interventional cardiology in Bemidji

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →